Anzeige
Mehr »
Dienstag, 29.07.2025 - Börsentäglich über 12.000 News
Warum Analysten in diesem veganen Gamechanger viel mehr sehen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A143G8 | ISIN: FR0013018124 | Ticker-Symbol: NXOA
München
29.07.25 | 08:01
0,334 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NICOX SA Chart 1 Jahr
5-Tage-Chart
NICOX SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,3310,40708:53

Aktuelle News zur NICOX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.07.Nicox Grants Kowa Rights To Develop, Commercialize NCX 4701
17.07.NICOX SA: Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories351Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with...
► Artikel lesen
30.06.NICOX SA: Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial346Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in...
► Artikel lesen
06.06.NICOX SA: Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of an ad hoc representative4
27.05.NICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan664Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese partner Kowa has received...
► Artikel lesen
14.05.Nicox Reports Positive Phase 3b Trial Results For NCX 470 In Intraocular Pressure Reduction2
14.05.NICOX SA: Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial342Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended...
► Artikel lesen
NICOX Aktie jetzt für 0€ handeln
30.04.Nicox reports FY results1
30.04.NICOX SA: Nicox Provides Full Year 2024 Financial Results306Press Release Nicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA's future...
► Artikel lesen
19.03.NICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial471Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali...
► Artikel lesen
06.03.NICOX SA: Nicox Extends Cash Runway into Q4 2025799Press Release Nicox Extends Cash Runway into Q4 2025 Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 monthsImmediate upfront payment from Vester Finance...
► Artikel lesen
03.03.NICOX SA: Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update488Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal...
► Artikel lesen
28.01.NICOX SA: Nicox Announces Scientific Presentation and Conference Attendance in H1 2025375Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 - release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124...
► Artikel lesen
21.01.NICOX SA: Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights513Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline...
► Artikel lesen
04.12.24NICOX SA: Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream615Press Release Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream First commercialized product from the Nicox-Ocumension...
► Artikel lesen
02.12.24NICOX SA: Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected467Press ReleaseNicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust...
► Artikel lesen
19.11.24NICOX SA: Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial486Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial An adaptive design is a useful clinical trial design tool which allowed identification...
► Artikel lesen
17.10.24NICOX SA: Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results405Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3...
► Artikel lesen
14.10.24NICOX SA: Nicox and Soleus Sign $16.5 million Royalty and Equity Financing400Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for the sale of Nicox's net share of the VYZULTA royalty to SoleusSoleus...
► Artikel lesen
23.09.24NICOX SA: Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement615Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1